Moreover, cells derived from a KRAS-driven pancreatic ductal adenocarcinoma (PDAC) genetically engineered mouse model (GEMM)38 revealed an inflammatory reprogramming upon trametinib treatment (Fig. 2c, Supplementary Fig. 4b). This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.